Cancer Pipeline (Breast Cancer, Adrenal Cortex) H2 2014 Therapeutics Review Reports

DALLAS, December 11, 2014 /PRNewswire/ --

RnRMarketResearch.com adds "Breast Cancer - Pipeline Review, H2 2014" and "Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2014" market research reports with latest 2014 data and information to its online business intelligence library.

These cancer pipeline review reports provide comprehensive information on the therapeutic development for Breast Cancer and Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer as well as Adrenocortical Carcinoma (Adrenal Cortex Cancer) and special features on late-stage and discontinued projects.

The Breast Cancer - Pipeline Review, H2 2014 market research report is available at http://www.rnrmarketresearch.com/breast-cancer-pipeline-review-h2-2014-market-report.html whereas the Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2014 therapeutic industry report is available at http://www.rnrmarketresearch.com/adrenocortical-carcinoma-adrenal-cortex-cancer-pipeline-review-h2-2014-market-report.html .

These cancer pipeline review reports for 2014 enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of these cancer pipeline review reports for H2 2014 cover the following that are common for both Breast Cancer as well as Adrenocortical Carcinoma (Adrenal Cortex Cancer): provides a snapshot of the global therapeutic landscape, reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities, reviews key players involved in the therapeutics development for Breast Cancer as well as Adrenocortical Carcinoma (Adrenal Cortex Cancer) and enlists all their major and minor projects along with summarizing all the dormant and discontinued pipeline projects. A review of the Breast Cancer and Adrenocortical Carcinoma (Adrenal Cortex Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages and detailed assessment of monotherapy and combination therapy pipeline projects is also provided. Coverage of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) and Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type as well as latest news and deals relating related to pipeline products are covered in the research.

Companies Involved in Therapeutics Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) mentioned and discussed in the H2 2014 pipeline review report include INSYS Therapeutics, Inc., Neotropix, Inc., Novartis AG, Orphagen Pharmaceuticals Inc, Pfizer Inc. and Tekmira Pharmaceuticals Corp. Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=242184 .

Companies mentioned and discussed in the Breast Cancer H2 2014 pipeline review report include 3-V Biosciences, Inc., A&G Pharmaceutical, Inc., A. Menarini Industrie Farmaceutiche Riunite Srl, AB Science, AbbVie Inc., AbGenomics International, Inc., Actinium Pharmaceuticals, Inc., Adaptimmune Limited, Advanced Cancer Therapeutics, Advaxis, Inc., Advenchen Laboratories, LLC, Aegis Therapeutics, LLC, Aerpio Therapeutics, Inc., Aeterna Zentaris Inc., Affichem, Aileron Therapeutics, Inc., Alchemia Limited, Alethia Biotherapeutics Inc., Almac Discovery Ltd., AlphaMab Co., Alteogen Inc., Ambrx, Inc., Amgen Inc., Ampio Pharmaceuticals, Inc., Amplyx Pharmaceuticals, Inc., Angion Biomedica Corp., AntiCancer, Inc., Antigen Express, Inc., Antoxis Limited, Aphios Corporation, Aptose Biosciences Inc., Armour Therapeutics Inc., Arno Therapeutics, Inc., Arrien Pharmaceuticals, LLC, Ascenta Therapeutics, Inc., Ascentage Pharma Group Corporation, Ltd., AstraZeneca PLC, Aurigene Discovery Technologies Limited, Avipep Pty Ltd, Axelar AB, Azaya Therapeutics Incorporated, Basilea Pharmaceutica AG, Bavarian Nordic A/S, Bayer AG, BBB Therapeutics B.V., BerGenBio AS, BHR Pharma, LLC, Bio-Path Holdings, Inc., Bionomics Limited, BioNTech AG, Bioo Therapeutics, BiOrion Technologies B.V., Biotecnol, Inc., Biotest AG, Biscayne Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Calithera Biosciences, Inc., Cancer Therapeutics CRC Pty Ltd, Cavion LLC, CEL-SCI Corporation, Celgene Corporation, Cellceutix Corporation, Celltrion, Inc., Celsion Corporation, Cerulean Pharma, Inc., China Grand Wuhan General Pharmaceutical Research Institute, Chipscreen Biosciences Ltd, Chong Kun Dang Pharmaceutical Corp., Chugai Pharmaceutical Co., Ltd., CIMAB S.A., Clovis Oncology, Inc., Cold Genesys, Inc., Compugen Ltd., Coronado Biosciences, Inc., Covagen AG, Critical Outcome Technologies Inc., Curadev Pharma Private Limited, Curaxys, S.L., CureFAKtor Pharmaceuticals. LLC, Curis, Inc., Cyclacel Pharmaceuticals, Inc., CytomX Therapeutics, Inc., CZ BioMed Corp, Daiichi Sankyo Company, Limited, Debiopharm International S.A., Deciphera Pharmaceuticals, LLC, Dendreon Corporation, DexTech Medical AB, Digna Biotech, S.L., DiNonA Inc., Dong-A Socio Group, and Dongkook Pharmaceutical Co., Ltd. Order a copy of this research at http://www.rnrmarketresearch.com/contacts/purchase?rname=244944 .

Explore more reports on the cancer therapeutics market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics .

Reasons to buy one or more of these cancer therapeutics pipeline review and related reports: 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Cancer
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Cancer pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Global Markets Direct reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
sales@rnrmarketresearch.com